期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

内皮素受体拮抗剂治疗肺动脉高压的研究进展 被引量：4

Medication of Pulmonary Arterial Hypertension: Novel Endothelin Receptor Antagonists
下载PDF
导出
摘要 近年来肺动脉高压的药物治疗多从调控内源性血管收缩因子(如内皮素-1、血栓素A2)和增殖介质(前列腺素和一氧化氮)的失衡入手。本文综述了基于内皮素-1途径的内皮素受体拮抗剂,如波生坦、安立生坦以及新近上市的macitentan,该类药物具有全身副作用小和口服优势,日益受到关注。 In recent years,drugs for the treatment of pulmonary arterial hypertension aimed at regulating the balance of endogenous vasoconstriction（such as endothelin-1,thromboxane A2） and proliferation medium（prostaglandins and nitric oxide） were rapidly developed. Currently available endothelin receptor antagonists including bosentan,ambrisentan and macitentan,with clinical advantages of minor system side effects and oral administration,are reviewed in this article.
作者 魏臻
机构地区 江苏省药学会
出处 《药学与临床研究》 2013年第6期660-664,共5页 Pharmaceutical and Clinical Research
关键词 肺动脉高压 内皮素受体拮抗剂 Macitentan 波生坦 安立生坦 Pulmonary arterial hypertension（PAH） Endothelin receptor antagonists Macitentan Ambrisentan Bosentan
分类号 R972 [医药卫生—药品]
  • 相关文献

参考文献20

  • 1Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-asso- ciated pulmonary arterial hypertension in the modem management era[J]. Circulation, 2010, 122: 156-63.
  • 2Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT)[J]. Eur Heart J, 2009, 30(20): 2493-537.
  • 3Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension [J]. J Clin Invest, 2012, 122(12): 4306-13.
  • 4Sweetman SC. Martindale The complete drug reference [B]. 36 ed. London, Chicago: Pharmaceutical Press, 2009.
  • 5荆志成.中国肺动脉高压治疗现状分析[EB/OL].http://www.365heart.eom/show/85245.shtml.2013-03-29.
  • 6Humbert M, Segal ES, Kiely DG, et al. Results of Eu- ropean post-marketing surveillance of bosentan in pul-monaty hypertension [J]. Eur Respir J, 2007, 30(2): 338-44.
  • 7Galie, N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hyper- tension, randomized, double-blind, placebo-controlled, nmlticenter, efficacy (ARIES) study 1 and 2[J]. Circula- tion, 2008. 117(23): 3010-9.
  • 8Galie N, et al. Ambrisentan therapy for pulmonary ar- terial hypertension [J]. JArn Coll Cardiol, 2005; 46: 529-35.
  • 9J Oudiz R J, Galie N, Olsehewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary ar- terial hypertension [J]. Am Coll Cardiol, 2009, 54(21): 1971-81.
  • 10何晶,文莉,姜蓉,赵勤华,王岚,蒋鑫,颜平,白蕾,荆志成.安立生坦治疗肺动脉高压患者的初步观察[J].中华心血管病杂志,2013,41(6):493-496. 被引量：6

二级参考文献13

  • 1荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量：98
  • 2中华医学会心血管病学分会 中华心血管病杂志编辑委员会.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35:979-987.
  • 3Rubin U. Primary pulmonary hypertension. N Engl J Med, 1997,336:111-117.
  • 4D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med, 1991, 115 :343-349.
  • 5Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest, 2007, 132 :373-379.
  • 6Zhang R , Dai lZ, Xie WP , et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest, 2011 ,140:301-309.
  • 7Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) , endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur HeartJ, 2009, 30 :2493-2537.
  • 8Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 2008,117 :3010-3019.
  • 9Badesch DB, FeldmanJ, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther ,2012,30 :93-99.
  • 10KlingerJR, Oudiz RJ, Spence R, et al. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. AmJ Cardiol, 2011 ,108:302-307.

共引文献5

同被引文献53

  • 1邝土光,王军,翟振国,王辰.波生坦治疗肺动脉高压疗效与安全性评价的Meta分析[J].中国医师进修杂志（内科版）,2006,29(12):17-20. 被引量：5
  • 2Bergot E,Sitbon 0, Cottin V,et al. Current epoprostenol use inpatients with severe idiopathic, heritable or anorexigen-associatedpulmonary arterial hypertension : data from the French pulmonaryhypertension registry[j]. Int J Cardiol, 2014,172(3) :561-567.
  • 3Simonneau G, Barst RJ, Galie N,et al. Continuous subcutaneousinfusion of treprostinil, a prostacyclin analogue, in patients withpulmonary arterial hypertension : a double-blind, randomized,placebo-controlled trial[j]. Am J Respir Crit Care Med, 2002,165(6):800-804.
  • 4Hiremath J, Thanikachalam S, Parikh K, et al. Exerciseimprovement and plasma biomarker changes with intravenoustreprostinil therapy for pulmonary arterial hypertension : a placebo-controlled trial [j]. J Heart Lung Transplant, 2010,29(2): 137-149.
  • 5McLaughlin VV, Benza RL, Rubin U, et al. Addition of inhaledtreprostinil to oral therapy for pulmonary arterial hypertension : arandomized controlled clinical trial [J]. J Am Coll Cardiol,2010,55(18):1915-1922.
  • 6Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for thetreatment of pulmonary arterial hypertension in patients onbackground endothelin receptor antagonist and/orphosphodiesterase type 5 inhibitor therapy (the FREEDOM-Cstudy): a randomized controlled trial [J]. Chest,2012,142(6):1383-1390.
  • 7Tapson VF, Jing ZC,Xu KF,et al. Oral treprostinil for thetreatment of pulmonary arterial hypertension in patients receivingbackground endothelin receptor antagonist and phosphodiesterasetype 5 inhibitor therapy (the FREEDOM-C2 study) : a randomizedcontrolled trial[ J]. Chest, 2013,144(3) :952-958.
  • 8McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study ofadding inhaled iloprost to existing bosentan in pulmonary arterialhypertension [j].Am J Respir Crit Care Med, 2006,174(11):1257-1263.
  • 9Rubin U, Badesch DB, Barst RJ,et al. Bosentan therapy forpulmonary arterial hypertension [J]. N Engl J Med, 2002,346(12):896-903.
  • 10Gali b N,Rubin U,Hoeper M,et al. Treatment of patients withmildly symptomatic pulmonary arterial hypertension with bosentan(EARLY study) : a double-blind, randomised controlled trial [J].Lancet,2008,371( 9630) : 2093-2100.

引证文献4

二级引证文献9

药学与临床研究
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部